Amicus Therapeutics Is Set To Revolutionize The Treatment Of Genetic Disorders

In just 10 years, Amicus Therapeutics has risen to the forefront of the biotechnology industry with a fresh approach to the treatment of genetic disorders and illnesses. The company’s own website boasts a wide range of drug therapies designed to treat a spectrum of rare genetic disorders.
Among the company’s greatest achievements, Amicus Therapeutics has recently unveiled a treatment for Fabry disease, a rare genetic disorder named for Johannes Fabry. The new course of treatments will be also be used to treat Pompe disease and other Lysosomal Storage Disorders through enzyme replacement therapy.
Developing a treatment plan for Lysosomal Storage Disorders is a tremendous advance, but it’s also the kind of thing this growing biotechnology company hopes to do regularly. Since its 2007 inception, Amicus Therapeutics has pledged to deliver the best possible treatments for people living with genetic diseases.
To maintain a vigilant focus on that directive, Amicus Therapeutics keeps a close eye on the community of families affected by rare and orphan genetic illnesses, providing them with support and offering new treatments, as they become available. In that vain, the biotechnology company is keeping an ear to the ground, looking for innovative ways to adapt new technologies and to outperform their own advances.
While Amicus Therapeutics’ own mission statement reveals a thirst for rapid advancement, the company is only limited by a desire for safety in their research and testing phases.
A code of conduct guides Amicus Therapeutics in all areas, from research and development to corporate decision making policies. A message from Patrik Florencio, Amicus Chief Compliance and Risk Officer, emphasizes that care for ethical actions on behalf of the company, ensuring that a concern for their patients won’t forsake greater concerns for the environments in which Amicus Therapeutics operates.
Speaking of their patients, Amicus Therapeutics takes their devotion to their patients into account, when considering new treatments. In searching for new treatments, Amicus collects research that will lead them toward more effective treatments for current and future patients. Incorporating patient input into developing each new therapy, Amicus Therapeutics remains at the forefront of the biotechnology industry .
Visit Amicus Therapeutics on Twitter or see job opportunities at Indeed


The Lung Institute Is Now A Key Player In The Stem Cell Industry

The Lung Institute is a well-known company in the American stem cell research industry. The company had gained great popularity at the International Congress convention in Italy. Jack Coleman was the representative for the company at this particular event.

The event was held to discuss the latest in stem cell research and the legal troubles surrounding it. Coleman is positive that the stem cells will reshape the medical industry, allowing for less medical costs for the common person. Traditional treatments are slow, expensive and rarely produce positive results. The current medical and scientific community is not very inviting to the world of stem cells.

In a report by PR Web, the presentation made by Jack Coleman involved the process of taking results from the lab to clinical trials. He emphasizes the difficulty of getting their reach into legal treatment plans. He argues that the current legal system is outdated and may cost future lives. The entirely regulatory system in the United States is controlled by a small group of biotech companies.

Chronic obstructive pulmonary disease (COPD) is one of the main illnesses that The Lung Institute targets. This disease will eventually get worse using conventional methods, so stem cells are the best hope for patients. The airflow from the lungs are greatly restricted, so doing simple tasks will be daunting. Many patients will also need to depend on oxygen for possibly their entire lives. Sufferers are also left vulnerable to other diseases. See,

Older people with a long history of cigarette smoking are especially prone to developing COPD. Smoking will cause inflammation and permanent damage to the lungs, so most smokers are in danger eventually. This is just another reason why people should avoid smoking.

Those with the rare genetic disorder Alpha-1-antitrypsin are also common receivers of the illness. A deficiency in alpha-1-antitrypsin will cause degeneration of the immune system in the lungs, so COPD preys upon people like this.

Regardless of the cause, COPD is very much treatable using stem cells. Most of the patients at The Lung Institute have nearly recovered from the disease, allowing them to return to their original lives. Some patients have gone from being bedridden to walking multiple miles per day.